Whalesbook
Avience Biomedicals’ IPO saw strong interest on its first day, with retail and non-institutional investors bidding nearly 10 times the offered shares. The diagnostics company aims to raise Rs 30.2 crore to fund a new manufacturing facility and boost working capital. Investors may watch the QIB category and post-listing liquidity trends.
What Happened
Avience Biomedicals, a provider of diagnostic solutions, opened its initial public offering (IPO) to a strong start on June 18. By the end of the first day, the issue was subscribed 9.68 times. The company is seeking to raise Rs 30.2 crore through the sale of 14.53 lakh shares, with the price band set between Rs 196 and Rs 208 per share.
The demand was primarily driven by non-institutional and retail investors. Non-institutional investors, which include high-net-worth individuals and corporate entities, bid 13.4 times the shares allocated to them. Retail investors showed even higher interest, with their segment subscribed 15.2 times. Qualified institutional buyers (QIBs), which typically include banks and mutual funds, have yet to begin their bidding process.
The Financial Picture
The company has demonstrated rapid financial growth recently. For the fiscal year ending March 2025, Avience Biomedicals reported a profit of Rs 7.2 crore, a significant jump from Rs 2.14 crore in the previous year. Revenue also saw a strong increase, rising by 88.8 percent to Rs 45.2 crore compared to Rs 24 crore in the prior year. Additionally, for the ten months ending January 2026, the company recorded a profit of Rs 5.7 crore on revenues of Rs 41.8 crore.
Why This Matters for Investors
For investors, an oversubscription on day one often reflects strong market sentiment toward the company’s growth prospects or the diagnostic solutions sector. The diagnostic industry in India has been growing, driven by a higher focus on healthcare. However, while the growth in revenue and profit is notable, it is important to remember that the company is a smaller player in a highly competitive market. Investors often look at whether this growth can be sustained once the company scales up its operations.
Expansion and Growth Strategy
A major focus of this IPO is the company's capital spending plan. Avience Biomedicals intends to use Rs 15.95 crore of the proceeds to set up a new manufacturing unit at the Medical Device Park in Uttar Pradesh. The remaining Rs 8.25 crore is earmarked for working capital needs, which helps cover day-to-day business expenses. This expansion is designed to increase capacity, which is essential for meeting rising demand, but it also ties the company’s future performance to the successful and timely execution of this project.
Risks and Considerations
Investing in smaller companies, often classified under the SME (Small and Medium Enterprise) segment, carries specific risks. These stocks can sometimes experience lower liquidity, meaning it may be harder to buy or sell large quantities of shares without affecting the price. Additionally, the company faces execution risk; if the construction of the new manufacturing unit in Uttar Pradesh is delayed or exceeds the planned budget, it could put pressure on the company's cash flow and future profitability.
Furthermore, the diagnostic products industry is highly competitive, with larger established players having deeper pockets and wider distribution networks. The company’s ability to maintain its profit margins in this competitive environment will be a key factor for long-term performance.
What Investors Should Track
Moving forward, investors may want to monitor a few key developments. The response from qualified institutional buyers (QIBs) over the next few days will provide a clearer picture of how large investors view the company's valuation. Post-listing, the market will look for updates on the construction of the new manufacturing unit and whether the company can maintain its current pace of revenue growth. Management's commentary on how they plan to manage competition and their working capital needs will also be important to understand the business's stability.
